Compare SCL & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCL | JANX |
|---|---|---|
| Founded | 1932 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 984.3M |
| IPO Year | 1994 | 2021 |
| Metric | SCL | JANX |
|---|---|---|
| Price | $57.92 | $14.95 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 13 |
| Target Price | ★ $75.00 | $47.00 |
| AVG Volume (30 Days) | 105.2K | ★ 940.4K |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.23% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,803,737,000.00 | $10,000,000.00 |
| Revenue This Year | $6.60 | N/A |
| Revenue Next Year | $5.27 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $41.82 | $12.12 |
| 52 Week High | $68.00 | $35.34 |
| Indicator | SCL | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 57.53 | 44.19 |
| Support Level | $48.96 | $13.13 |
| Resistance Level | $59.21 | $15.49 |
| Average True Range (ATR) | 1.97 | 0.63 |
| MACD | -0.17 | -0.17 |
| Stochastic Oscillator | 53.31 | 16.27 |
Stepan Co manufactures and sells a variety of chemicals and chemical-based products. The company organizes itself into three segments based on product type. The surfactants segment, which generates the majority of revenue, sells cleaning agents used in detergents, shampoos, body wash, fabric softeners, toothpastes, and other personal-care products. The polymers segment sells polyurethane used to manufacture rigid foam for thermal insulation, as well as phthalic anhydride used to make plastic components for the construction, automotive, and boating industries. The specialty products segment sells chemicals used in food and flavoring. The majority of Stepan's revenue comes from the United States, followed by France, Poland, the United Kingdom, Brazil, Mexico, and other countries.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.